Patients with diabetes who were prescribed GLP-1 receptor agonists were less likely to be diagnosed with depression and anxiety compared to those not on these medications. The GLP-1 receptor agonists included semaglutide, tirzepatide, dulaglutide, exenatide, and liraglutide. Patients without diabetes prescribed semaglutide also had a lower risk for anxiety and depression. Although the findings suggest reduced odds for depression and anxiety, further investigation is needed, according to a clinician from Epic Research. There were conflicting opinions from two perspectives provided on the study, with some raising questions and others finding the results interesting but wanting more information.
Source link
GLP-1s associated with reduced risk for depression, anxiety in patients with diabetes
